Octavio Espinoza

Octavio Espinoza appears in our data through filings on Ligand Pharmaceuticals Inc shares, published by SEC (Form 4). In total, 39 filings cover trades dated from 9 November 2022 to 12 August 2026.

In open-market terms, that means 1 purchase worth €93k on one side and 7 sales worth €9.7M on the other. The net balance comes to €9.6M on the selling side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Outside the open market, there are 13 share grants and 12 option exercises. So far in 2026, the count stands at no purchases and 1 sale.

Most recently, on 14 August 2026, the filings show an option exercise worth €199k in Ligand Pharmaceuticals Inc. The latest purchase dates back some time: it was published 523 days ago, on 13 May 2025. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.